https://orcid.org/0000-0002-4655-774X
Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Shabnam ShahAli, Haniyeh Choobsaz & Reyhane Ebrahimi. (2023) COVID-19 related knowledge, anxiety, depression and physical activity among Iranian people with relapsing-remitting multiple sclerosis during COVID-19 pandemic: an online cross-sectional survey. European Journal of Physiotherapy 25:1, pages 43-50.
Read now
Read now
Articles from other publishers (30)
Ghazaleh Hajiluian, Sahar Jafari Karegar, Farzad Shidfar, Naheed Aryaeian, Masoud Salehi, Teyebeh Lotfi, Pooya Farhangnia, Javad Heshmati & Ali-Akbar Delbandi. (2023) The effects of Ellagic acid supplementation on neurotrophic, inflammation, and oxidative stress factors, and indoleamine 2, 3-dioxygenase gene expression in multiple sclerosis patients with mild to moderate depressive symptoms: A randomized, triple-blind, placebo-controlled trial. Phytomedicine 121, pages 155094.
Crossref
Crossref
W. Daniel Chapman, Megan C. Herink, Michelle H. Cameron & Dennis Bourdette. (2023) Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation Strategies. Current Neurology and Neuroscience Reports 23:9, pages 521-529.
Crossref
Crossref
Julia Baldt, Niklas Frahm, Michael Hecker, Barbara Streckenbach, Silvan Elias Langhorst, Pegah Mashhadiakbar, Katja Burian, Janina Meißner, Felicita Heidler, Jörg Richter & Uwe Klaus Zettl. (2023) Depression and Anxiety in Association with Polypharmacy in Patients with Multiple Sclerosis. Journal of Clinical Medicine 12:16, pages 5379.
Crossref
Crossref
Gabrielle Macaron, Catherine Larochelle, Nathalie Arbour, Manon Galmard, Jean Marc Girard, Alexandre Prat & Pierre Duquette. (2023) Impact of aging on treatment considerations for multiple sclerosis patients. Frontiers in Neurology 14.
Crossref
Crossref
Christos Bakirtzis, Ioannis Nikolaidis, Marina-Kleopatra Boziki, Eleni Grigoriadou, Maria-Valeria Karakasi, Theodoros Moysiadis, Evangelia Kesidou, Georgios Papazisis & Nikolaos Grigoriadis. (2023) Epidemiological Insights on Medication Concurrency and Polypharmacy in People With Multiple Sclerosis in Greece. International Journal of MS Care 25:4, pages 140-144.
Crossref
Crossref
Alejandro Santiago Pérez, Santos Esteban Casado, Miriam Álvarez Payero, Ángel Escolano Pueyo, Ángel Guillermo Arévalo Bernabé, Núria Padullés Zamora, Pilar Diaz Ruiz & Ana María López González. (2023) [Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain. Farmacia Hospitalaria 47:4, pages T155-T160.
Crossref
Crossref
Alejandro Santiago Pérez, Santos Esteban Casado, Miriam Álvarez Payero, Ángel Escolano Escolano Pueyo, Ángel Guillermo Arévalo Bernabé, Núria Padullés Zamora, Pilar Diaz Ruiz & Ana María López González. (2023) Tratamientos modificadores de la enfermedad en pacientes con esclerosis múltiple en España. Farmacia Hospitalaria 47:4, pages 155-160.
Crossref
Crossref
Zahra Amiri, Mehrdad Azmin, Shiva Amiri, Ali Akbarisari, Mohammad Ali Sahraian, Farshad Farzadfar & Fatemeh Soleymani. (2023) Prevalence of comorbidities in patients with multiple sclerosis using administrative data from 2007 to 2016 in Iran. Multiple Sclerosis and Related Disorders 74, pages 104693.
Crossref
Crossref
Sharon Roman. (2023) A spoonful of sugar: The risks of negative health outcomes of polypharmacy in MS is a bitter reality. Multiple Sclerosis Journal 29:6, pages 765-766.
Crossref
Crossref
Sara J.T. Guilcher, Lauren Cadel, Andrea He, Stephanie R. Cimino, Maham Ahmed, Chester H. Ho, Sander L. Hitzig, Lisa M. McCarthy, Tejal Patel, Shoshana Hahn-Goldberg, Aisha K. Lofters & Tanya L. Packer. (2023) Medication self-management toolkits for adults with multiple sclerosis: A scoping review. Exploratory Research in Clinical and Social Pharmacy, pages 100282.
Crossref
Crossref
Marie-Celine Haker, Niklas Frahm, Michael Hecker, Silvan Elias Langhorst, Pegah Mashhadiakbar, Jane Louisa Debus, Barbara Streckenbach, Julia Baldt, Felicita Heidler & Uwe Klaus Zettl. (2023) Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy. Therapeutic Advances in Drug Safety 14, pages 204209862211438.
Crossref
Crossref
Dennis Bourdette & Megan Herink. (2022) Polypharmacy in multiple sclerosis: More is not necessarily better. Multiple Sclerosis Journal 29:1, pages 3-5.
Crossref
Crossref
Anibal Chertcoff, Huah Shin Ng, Feng Zhu, Yinshan Zhao & Helen Tremlett. (2022) Polypharmacy and multiple sclerosis: A population-based study. Multiple Sclerosis Journal 29:1, pages 107-118.
Crossref
Crossref
Michael Hecker, Niklas Frahm, Paula Bachmann, Jane Louisa Debus, Marie-Celine Haker, Pegah Mashhadiakbar, Silvan Elias Langhorst, Julia Baldt, Barbara Streckenbach, Felicita Heidler & Uwe Klaus Zettl. (2022) Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases. Frontiers in Pharmacology 13.
Crossref
Crossref
Massimiliano Mirabella, Pietro Annovazzi, Wallace Brownlee, Jeffrey A. Cohen, Christoph Kleinschnitz & Christian Wolf. (2022) Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?. Frontiers in Neurology 13.
Crossref
Crossref
Paula Bachmann, Niklas Frahm, Jane Louisa Debus, Pegah Mashhadiakbar, Silvan Elias Langhorst, Barbara Streckenbach, Julia Baldt, Felicita Heidler, Michael Hecker & Uwe Klaus Zettl. (2022) Prevalence and Severity of Potential Drug–Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy. Pharmaceutics 14:3, pages 592.
Crossref
Crossref
Niklas Frahm, Firas Fneish, David Ellenberger, Peter Flachenecker, Friedemann Paul, Clemens Warnke, Christoph Kleinschnitz, Tina Parciak, Dagmar Krefting, Kerstin Hellwig, Judith Haas, Paulus S. Rommer, Alexander Stahmann & Uwe K. Zettl. (2022) Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry. Neurology and Therapy 11:1, pages 319-336.
Crossref
Crossref
Marcel Gebhardt, Peter Kropp, Frank Hoffmann & Uwe K. Zettl. (2022) Headache in Multiple Sclerosis - Pharmacological Aspects. Current Pharmaceutical Design 28:6, pages 445-453.
Crossref
Crossref
Emerson Sebastião, Tyler Wood, Robert Wayne Motl, Felipe Balistieri Santinelli & Fabio Augusto Barbieri. (2022) The importance of promoting physical activity and exercise training as adjuvant therapy for people with multiple sclerosis. Motriz: Revista de Educação Física 28.
Crossref
Crossref
Jane Louisa Debus, Paula Bachmann, Niklas Frahm, Pegah Mashhadiakbar, Silvan Elias Langhorst, Barbara Streckenbach, Julia Baldt, Felicita Heidler, Michael Hecker & Uwe Klaus Zettl. (2022) Associated factors of potential drug-drug interactions and drug–food interactions in patients with multiple sclerosis. Therapeutic Advances in Chronic Disease 13, pages 204062232211083.
Crossref
Crossref
Marianna Cortese, Kjetil Bjornevik, Tanuja Chitnis, Alberto Ascherio & Kassandra L Munger. (2021) Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women. Multiple Sclerosis Journal 28:1, pages 121-131.
Crossref
Crossref
. 2022. Multiple Sklerose. Multiple Sklerose
468
512
.
Francesco Patti, Javier Nicolas Penaherrera, Lorissa Zieger & Eva-Maria Wicklein. (2021) Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study. BMC Neurology 21:1.
Crossref
Crossref
Niklas Frahm, Michael Hecker & Uwe Klaus Zettl. (2021) Polypharmacy in Chronic Neurological Diseases: Multiple Sclerosis, Dementia and Parkinson’s Disease. Current Pharmaceutical Design 27:38, pages 4008-4016.
Crossref
Crossref
Oscar Fernandez, Lucienne Costa-Frossard, Maria Luisa Martínez-Ginés, Paloma Montero, Jose María Prieto-González & Lluís Ramió-Torrentà. (2021) Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat® Methodology. Frontiers in Neurology 12.
Crossref
Crossref
Niklas Frahm, Melanie Peters, Jörg Bätzing, David Ellenberger, Manas K. Akmatov, Judith Haas, Paulus S. Rommer, Alexander Stahmann, Uwe K. Zettl & Jakob Holstiege. (2021) Treatment patterns in pediatric patients with multiple sclerosis in Germany—a nationwide claim-based analysis. Therapeutic Advances in Neurological Disorders 14, pages 175628642110483.
Crossref
Crossref
Gisela Zanga, Estefania Drzewiscki, Paula Tagliani, Maximiliano Smietniansky, Maria M. Esnaola y Rojas & Diego Caruso. (2021) Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis. Therapeutic Advances in Neurological Disorders 14, pages 175628642110310.
Crossref
Crossref
Marcel Gebhardt, Peter Kropp, Frank Hoffmann & Uwe K. Zettl. (2020) Kopfschmerzen bei Multipler SkleroseHeadache in multiple sclerosis. Der Nervenarzt 91:10, pages 926-935.
Crossref
Crossref
Lucia Moiola, Paulus S. Rommer & Uwe K. Zettl. (2020) Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis. Current Opinion in Neurology 33:3, pages 286-294.
Crossref
Crossref
Niklas Frahm, Michael Hecker, Silvan Elias Langhorst, Pegah Mashhadiakbar, Marie-Celine Haker & Uwe Klaus Zettl. (2020) The risk of polypharmacy, comorbidities and drug–drug interactions in women of childbearing age with multiple sclerosis. Therapeutic Advances in Neurological Disorders 13, pages 175628642096950.
Crossref
Crossref